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INTRODUCTION
The tricuspid valve was virtually ignored for a long
time in the past. However, the incidence of tricuspid
insufﬁciency associated with left valvular disease is
quite signiﬁcant, ranging from 8% to 35% of
cases.1 2 This is most common in conjunction with
mitral valve disease but association with aortic valve
pathology is not uncommon. It is most frequently
related to rheumatic valve disease and much rarer in
association with degenerative mitral valve disease. In
most cases, the tricuspid regurgitation (TR) is
so-called ‘functional’, corresponding to dilatation of
the annulus, as a consequence of RV dilatation sec-
ondary to pulmonary hypertension. In 15–20% of
cases, however, the injury can be organic, generally
of rheumatic origin, but for the purposes of this
work we will restrict our analysis to secondary (ter-
minology now preferred over functional) TR.
Originally, it was thought that in most patients
with secondary TR, surgical treatment of the mitral
valve disease would correct the problems of the
right side and, hence, a conservative (no touch)
approach to the tricuspid valve was
recommended.3 4
More recently, however, it has become evident
that in a signiﬁcant number of cases secondary TR
does not regress after appropriate correction of the
left-side valvulopathy. Thus, the indications for
surgery of the TR have moved towards a progres-
sively more interventional attitude. Today, it is
evident that we must intervene on the tricuspid
valve in cases of obviously severe tricuspid insufﬁ-
ciency and in cases where perioperative detection of
a more signiﬁcant TR than expected is made, espe-
cially when triggered by increasing load
conditions.5 6
In this work, we intend to review the current
concepts on the anatomy, physiopathology, natural
history, diagnosis and treatment of secondary TR.
ANATOMY
The tricuspid valve is the largest of the heart valves
with an anatomical area of 4–6 cm2 and a diameter
of 27–29 mm. It lies inferiorly and anteriorly to
the mitral valve, the distance between the mitral
and tricuspid annulus being, in normal conditions,
inferior to 8 mm/m2 (displacement index).7 Its ana-
tomical structure is complex and constituted of the
three leaﬂets, the annulus, the chordae, the papil-
lary muscles and the adjacent myocardium (atrial
and ventricular). The correct function of the valve
depends on the integrity and coordination of all
these structures (ﬁgure 1).
The septal leaﬂet is the most medial and is
attached directly to the interventricular septum, the
anterior leaﬂet is usually the largest and extends
through the anterior portion of the annulus, and the
posterior leaﬂet, the smallest, extends through the
inferior and posterior edges of the annulus. The
anterior papillary muscle is the most prominent; it
partially originates from the moderator band and
provides chordae to the anterior and posterior leaf-
lets. The septal papillary muscle is less prominent,
even absent in 20% of cases and often rudimentary,
providing chordae to the septal and posterior leaf-
lets. Finally, the posterior papillary muscle is often
bifurcated or trifurcated and provides chordae to
the posterior and septal leaﬂets.8 There are also mul-
tiple accessory chordae attached to the free wall of
the RV and to the moderator band. These are
important because they may prevent proper leaﬂet
coaptation in case of dilatation or dysfunction of the
RV, thus causing TR.
The tricuspid annulus has a dynamic and complex
3D structure that differs from the more symmetrical
‘saddle-shaped’ mitral annulus. A normal tricuspid
annulus has a non-planar, elliptical-shaped morph-
ology, the posteroseptal portion being the lowest
part and the anteroseptal portion the highest.9 In
patients with secondary TR, the annulus becomes
dilated (greater increase in the anteroposterior diam-
eter compared with the mediolateral diameter, con-
sistent with greater dilatation along the RV free
wall), more planar and circular.10 11
PATHOPHYSIOLOGY
Secondary TR is the most frequent type and refers
to regurgitation not related to primary organic
tricuspid valve disease. The pathophysiology of sec-
ondary TR is related to RV and annular dilatation
or tethering (even with little annular dilatation)12
in connection to pulmonary hypertension. In most
cases this is secondary to left-side valvular diseases,
but can also occur in primary RV disease or pul-
monary hypertension. Some authors have demon-
strated that loss of contraction of the myocardium
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surrounding the annulus is the leading mechanism
of TR,13 thus atrial ﬁbrillation can also contribute.
With progressive dilatation of ventricle and
annulus, there is a failure of coaptation and tether-
ing of the leaﬂets with progression of the TR.
CLINICAL DIAGNOSIS
TR is most often diagnosed at the time of echocar-
diographic evaluation of left-side heart disease or
evaluation of right heart failure. As indicated above,
TR is relatively well tolerated and patients may
remain asymptomatic even with TR of moderate or
severe degree. When symptoms appear, patients may
complain of asthenia, fatigue or decreased exercise
tolerance as a result of lower cardiac output. They
may also present with signs of elevated right atrial
pressure, such as peripheral oedema and abdominal
fullness, congestive hepatomegaly and ascites.
Physical examination ﬁndings include jugular venous
distension with a prominent v-wave, hepatomegaly
and, rarely, a soft systolic regurgitant murmur can be
heard that increases during inspiration owing to the
increased venous return. Atrial ﬁbrillation as a result
of right atrial enlargement is common.
IMAGING OF TRICUSPID REGURGITATION AND
RIGHT VENTRICULAR FUNCTION
Evaluation of patients with TR requires the integra-
tion of the information from different cardiac
imaging techniques (ﬁgure 2). Before left-side valve
surgery, careful assessment of the severity of TR
and careful measurement of the tricuspid annulus is
mandatory.
Transthoracic echocardiography
Transthoracic echocardiography (TTE) is the tech-
nique of choice to evaluate the aetiology of the TR,
quantify its severity and determine the annular
diameters. Simultaneous evaluation of the three
leaﬂets is difﬁcult by conventional TTE, requiring
the use of different projections for the correct
assessment (long-axis view of RV inﬂow, short-axis
at the level of the aortic valve, apical four-chamber
and subcostal views). The normal annulus diameter
in adults is 28±5 mm and signiﬁcant dilatation is
deﬁned by a diastolic diameter >40 mm or
>21 mm/mm2. Of note, it has been demonstrated
that the annular diameter, as measured from the
apical four-chamber view, underestimates major
and minor annular dimensions.10
Quantiﬁcation of the severity of the TR depends
on the combination of different echocardiographic
parameters. Box 1 summarises the main parameters
characterising severe TR, according to the recom-
mendations for the echocardiographic assessment
of native valvular regurgitation from the European
Association of Cardiovascular Imaging.14
TTE also allows assessment of RV diameters
and function in patients with TR. However, this
technique has limitations given the complex
Figure 1 Anatomy of the tricuspid valve (A) and normal tricuspid annulus (C, left image) with a non-planar morphology with highest points in the
anteroposterior direction and the lowest in the mediolateral. In patients with functional tricuspid regurgitation, the annulus becomes more planar
(C, right image) and dilated in the anteroposterior diameter (B). A: anterior, P: posterior; RA, right atrium; TR, tricuspid regurgitation. Adapted from
Shinn and Schaff.11
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morphology of the RV and that most parameters
are inﬂuenced by load conditions. Reference
values according to the recommendations for
cardiac chamber quantiﬁcation by the American
Society of Echocardiography and the European
Association of Cardiovascular Imaging are dis-
played in table 1.15
In addition, TTE also predicts the presence of
residual TR post surgery. The severity of TR, the
degree of RV dysfunction, a tenting area
>1.63 cm2 and a depth of tethering >0.76 cm are
good indicators of signiﬁcant residual TR.9
However, the severity of the TR changes within
the respiratory cycle. During inspiration, the tricus-
pid regurgitant oriﬁce increases (median of 69%)
and the peak TR velocity decreases leading to a
smaller change in the regurgitant volume (median
of 20%). These changes of the regurgitant oriﬁce
are related to an inspiratory increase in RV size and
morphology resulting in tricuspid annular dilata-
tion, tethering and deﬁcit of leaﬂet coaptation.16
Recently, Mutlak et al17 showed a difference in the
peak TR velocity between inspiration and expir-
ation ≥0.6 m/s, with a sensitivity of 66% and speci-
ﬁcity of 94% for diagnosis of severe TR.
Transoesophageal echocardiography
Transoesophageal echocardiography is only indicated
when it is not possible to assess the aetiology of TR by
TTE because of poor echocardiographic window.14
Additionally, transoesophageal echocardiography is
indicated in patients with left prosthetic valves and TR
to ensure normal function before surgery of the tricus-
pid valve. It is also more useful intraoperatively, espe-
cially to assess the ﬁnal result of repair.
In recent years, real-time 3D TTE has become a
basic tool for the assessment of tricuspid valve
pathology, since it permits simultaneous
Figure 2 Multimodality assessment of the tricuspid valve and RV volumes and function. (A) 3D echocardiographic assessment of the tricuspid
valve. (B) Colour Doppler regurgitant ﬂow in massive TR. (C) Dense/triangular ﬂow with early systolic peak in a patient with massive TR. (D) Cine
short-axis view showing right and left mass and volumes assessed by MRI. S, septal leaﬂet; P, posterior leaﬂet; A, anterior leaﬂet; TR, tricuspid
regurgitation.
Box 1 Echocardiographic parameters of severe tricuspid
regurgitation (TR)
Doppler derived parameters
▸ Colour Doppler regurgitant ﬂow >30% of the area of the right atrium
▸ Dense/triangular ﬂow with early systolic peak (maximum velocity <2 m/s
in massive TR)
▸ Vena contracta width ≥7 mm
▸ PISA in tricuspid regurgitation
– PISA* radius >9 mm at Nyquist limit of 28 cm/s
– EROA* ≥40 mm2 or regurgitant volume ≥45 mL
▸ Systolic ﬂow reversal in hepatic vein ﬂow
▸ Tricuspid inﬂow (E-wave) ≥1 m/s
Indirect parameters
▸ Abnormal/ﬂail/large coaptation defect (tenting area >1 cm2)
▸ Inferior vena cava ≥21 mm with <50% collapse
▸ RV enlargement (RV eccentricity index >2)*
*Obtained by dividing the longest right lateral distance by the distance
connecting the ventricular septum and the RV free wall.
▸ PISA, proximal isovelocity surface area; EROA, effective regurgitant oriﬁce
area.
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visualisation of the three leaﬂets, the commissures
and the anatomy of the annulus in a short-axis
view.
Cardiovascular magnetic resonance
Cardiovascular magnetic resonance (CMR) permits
visualisation of the anatomy and function of the tri-
cuspid valve. It also permits quantiﬁcation of the
regurgitant volume and regurgitant fraction.18
However, the most important role of CMR in
TR is in the assessment of the LV and RV volumes
and EF, since both parameters have been consid-
ered independent predictors of signiﬁcant residual
TR post surgery.9 CMR has been considered the
gold standard technique to evaluate the ventricular
volumes, due to its accuracy and reproducibility.
Reference values for healthy adults (not for severe
TR) are displayed in table 1.19
There are no deﬁned cut-off values in terms of
RV volumes or EF to indicate surgery in patients
with TR. Kim et al studied 31 patients with CMR
previous to tricuspid valve surgery and suggested
that a preoperative RV end-diastolic volume of
164 mL/m2 effectively discriminated patients with
normal RV EF from those with depressed EF at
follow-up.20 However, based on the European
Society of Cardiology (ESC) guidelines for the
management of grown-up congenital heart disease,
signiﬁcant RV enlargement exists when the end-
diastolic volume is ≥150 mL/m2 and signiﬁcant RV
dysfunction when the EF is ≤45%.21
NATURAL HISTORY AND FOLLOW-UP
The natural history of severe TR includes a pro-
longed asymptomatic period with progressive
enlargement of the right atrium and RV due to
volume overload. There are limited data regarding
predictors of TR progression. Recently, Shiran
et al22 reported that increased pulmonary artery
pressure and permanent atrial ﬁbrillation were the
most powerful risk factors for TR progression. The
disease was considered benign unless associated
with pulmonary hypertension or right or left heart
failure. However, Nath et al23 examined the mor-
tality associated with TR in a retrospective series of
5223 patients with a follow-up of 4 years. They
concluded that moderate and severe TR were asso-
ciated with increased mortality and also that
increasing TR severity was associated with worse
survival regardless of biventricular systolic pressure
and pulmonary hypertension. Also, it has to be
emphasised that uncorrected severe TR is self-
perpetuating and progressive and becomes very
incapacitating, with patients needing large amounts
of diuretics and frequently developing liver
dysfunction.
Jhawar et al24 also found that secondary TR is
associated with increased mortality and decreased
surgery-free survival. Due to its functional physi-
ology, secondary TR may diminish or disappear
with improvement of the RV function and also after
successful correction of left-side lesions. However,
TR can persist or even increase after left-heart
surgery,25 26 hence tricuspid valve repair at the time
of mitral surgery is nowadays recommended in cases
of severe TR or dilated tricuspid annulus.6 27
The prognostic role of pulmonary hypertension
is still controversial. It appears that patients with
moderate pulmonary hypertension preoperatively
generally have RV failure and dilatation, and many
of these patients maintain TR after mitral valve
surgery, when not dealt with simultaneous surgery
of the tricuspid valve. On the other hand, patients
with severe pulmonary hypertension often show
regression of TR and almost a third of them experi-
ence complete resolution following mitral surgery
without intervention on the tricuspid valve.28
Other factors such as age, atrial ﬁbrillation and
the presence of a pacemaker lead are also related to
persisting TR and worse outcome.29
In patients with moderate and severe TR, echo-
cardiographic follow-up to monitor RV function is
recommended. Before considering isolated surgery
for the tricuspid valve, in particular redo surgery
for severe TR after left-side surgery (see below),
information is needed to rule out any signiﬁcant
residual or recurrent left-side valvular lesions
(or prosthetic dysfunction), and to deﬁne the
systolic pulmonary pressure and the volume and
function of both ventricles. Based on our clinical
experience, we propose the algorithm for follow-up
and surgical indication shown in ﬁgure 3.
INDICATIONS FOR SURGERY
Perspectives of the problem
There are various problems in solving the equation
of the treatment of secondary tricuspid valve regur-
gitation. First is the deﬁnition of the indications for
surgery; second, the choice between repair and
Table 1 Echocardiographic (A) and cardiovascular
magnetic resonance (B) reference values of RV and
right atrial size and function in healthy adults
Abnormal
(A) Echocardiography
RV diameter (mm)
Base* >41
Midventricular level* >35
Length* >83
RV wall thickness (subcostal view) (mm) >5
RA end-systolic area (mm2) >18
RA volume (mL/m2) >30
Systolic function
TAPSE (mm) <17
Pulsed Doppler peak S0 (m/s) <9.5
RV fractional area change (%) <35
RV 3D EF (%) <45
Diastolic function
E/E0 ratio >6
Tissue Doppler MPI >0.54
(B) Cardiovascular magnetic resonance
End-diastolic volume/BSA (mL/m2) >108
End-systolic volume/BSA (mL/m2) >48
EF (%) <50
Mass/BSA (g/m2) >46
BSA, body surface area; MPI, myocardial performance index; RA,
right atrium; TAPSE, tricuspid annular plane systolic excursion.
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replacement of the tricuspid valve; and third, the
effectiveness of different methods of repair and/or
the type of prosthesis to be used in case of
replacement.
With respect to indications, the decision is difﬁ-
cult because there is no reliable method of judging
the degree of reversibility after correction of the
problems on the left-side valves, the quantiﬁcation
of the TR is difﬁcult as there are no reproducible
methods to measure it, and, ﬁnally, there are no sat-
isfactory methods of assessment of RV function.
On the other hand, if there is no argument about
the need to intervene on severe TR, the question of
what to do with lesser degrees of TR remains
unanswered. Finally, how to predict which patients
will return after successful surgery of the mitral
valve with persistent symptomatic TR?
As discussed above, one good reason for inter-
vening on the tricuspid valve during left heart valve
surgery is that secondary TR accompanied by
marked dilatation of the annulus can produce an
irreversible deterioration of RV function, and it is
well known that RV dysfunction affects the post-
operative prognosis negatively.30 In addition, the
surgical risk is also increased in cases where there is
a signiﬁcant degree of clinical and haemodynamic
deterioration.
It is also evident that the quality of ‘repair’ of the
left-side valvulopathy plays a key role in the evolu-
tion of the disease. Any incomplete or unsatisfactory
result is usually associated with persistence of TR.
But even with a perfect and complete repair of the
left heart disease, in many cases progression of the
TR can occur and surgery for isolated TR may be
necessary. A much referred work by Dreyfus et al6
appeared to demonstrate that tricuspid valves with a
dilated annulus, even without or with minimal
regurgitation, often evolved to more severe degrees
of regurgitation. The authors measured, intraopera-
tively, the larger diameter of the tricuspid valve
between the commissures bordering the anterior
leaﬂet and found values above 70 mm to be predict-
ive of negative outcome. These values correspond to
the 40 mm measured by echocardiography. In prac-
tice, the latter is more relevant as the decision to
intervene on the tricuspid valve must be made
before the patient goes on the operating table.
Recommendations for TR surgery at the time
of left heart valve surgery
Naturally, severe secondary TR requires interven-
tion during surgery of the mitral or the aortic
valve, and this is a class I indication, but current
ESC guidelines (2012) have been modiﬁed from
previous ones and suggest that ‘surgery should be
considered in patients with mild or moderate sec-
ondary TR with dilated annulus (>40 mm or
21 mm/m2) undergoing left-side valve surgery’
(Class IIa indication, level of evidence C).w31
The American Heart Association/American
College of Cardiology (AHA/ACC) guidelines
(2014) give very similar recommendations, in add-
ition indicating that ‘tricuspid valve repair may be
considered for patients with moderate functional
Figure 3 Proposed algorithm of management and follow-up of patients with isolated TR. CMR, cardiovascular magnetic resonance; TR, tricuspid
regurgitation.
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TR and pulmonary artery hypertension at the time
of left-side valve surgery’ (Class IIa indication, level
of evidence C).28
For the time being, there is no sufﬁcient scientiﬁc
evidence for acting in cases of minimal or absent
TR (prophylactic use?), even in the cases of signiﬁ-
cant dilatation of the tricuspid annulus.
SURGICAL TECHNIQUES
It is generally believed that the long-term results of
tricuspid annuloplasty are more favourable than
those obtained after valve replacement, whether by
mechanical or bioprosthetic implants.
Survival after tricuspid valve replacement has
been reported as low as 35% and up to 75% after
10 years,27 w32 w33 naturally depending on the
population and pathology, but these numbers are
clearly lower than those that are observed after tri-
cuspid annuloplasty, as well as those observed in
the general population,w34 although some found
no signiﬁcant differences.w35 And the choice of
prosthesis—mechanical or biological—is still con-
troversial, each type having advantages and disad-
vantages,w36 but, again with not much scientiﬁc
evidence of differences in survival.
Therefore, we believe that only exceptionally
should the tricuspid valve be replaced. Evidently,
annuloplasty is the surgery of choice in these
conditions, also because the valve tolerates very
well a less than perfect result, with regards to mild
degrees of residual regurgitation.
The most used operation on the tricuspid valve
was the De Vega annuloplasty, ﬁrst described in
1972,w37 which is based on the fact that the dilata-
tion of the tricuspid annulus occurs mainly in its
anterior and posterior segments, while remaining
generally unchanged in the septal portion, a concept
developed by Carpentier et alw38 (ﬁgure 1). Other
methods of suture annuloplasty, including several
forms of bicuspidisation,w39 have been used by
several authors but, in our experience (MJA), a
modiﬁed De Vega technique, by interposition of
Teﬂon felt pledgets for each annular bite of the
suture, thus minimising the risk of tearing, which
we have described more than three decades ago, has
consistently produced excellent results (ﬁgure 4).w40
On the other hand, an increasing number of
authors consider it important to use a prosthetic
ring. Rigid rings or bands of various types have
been used to remodel the posterior and anterior
segments of the annulus (ﬁgure 5). The annular
remodelling concept, by contrast with simple nar-
rowing, is appealing and several studies appeared to
prove greater freedom from recurrent TR in the
long-term follow-up, although this has generally
not translated into better patient survival.w41 w42
Figure 4 Suture annuloplasty: De Vega (A) and modiﬁed De Vega annuloplasty (B).
Figure 5 Ring annuloplasty (Left—in diastole; Right—during systole).
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The use of a ring is speciﬁcally indicated when
there is organic involvement of the tricuspid valve,
usually associated with stenosis, generally of
rheumatic origin, in which case a commissurotomy
is usually also required.
RESULTS OF TV SURGERY
In a recent report, Kim et al, concluded that long-
term survival after TV surgery for severe TR was
‘affected by several preoperative factors including
advanced heart failure symptoms, comorbidity,
end-organ dysfunction and laboratory abnormal-
ities, but not by the type of surgery or causes of
TR’.w43 w44
As discussed above, although currently most
people claim better results with rings than with
suture annuloplasties, there is no evidence that this
impacts on survival. Similar considerations may be
made for valve replacement versus repair, although
here we have to recognise the adverse impact of
prosthetic-related complications, which tend to
appear late in the follow-up.
In fact, the results of annuloplasty alone are not
always consistent. Among other factors, this may be
related to the degree of narrowing of the tricuspid
oriﬁce, hence it has been suggested that the size of
the tricuspid annulus should be reduced appropri-
ately considering patients’ body size to prevent
recurrent TR.w45
On the other hand, tenting of the tricuspid valve
in cases of signiﬁcant dilatation of the RV is known
to be a factor for persisting or recurrent regurgita-
tion. In these cases, some authors have suggested
pericardial patch enlargement of the tricuspid lea-
ﬂets.w46 The edge-to-edge ‘clover’ technique has
also been suggested in these circumstances.w47
Finally, there appears to be little difference
between replacement with bioprostheses and mech-
anical valves. Mechanical valves in the tricuspid
position in multivalvular procedures are generally
associated with higher mortality and also with
increased incidence of thromboembolic complica-
tions and valvular dysfunction by pannus; although
thrombolysis appears to lead to more favourable
results here. On the other hand, bioprostheses
appear to degenerate faster in the tricuspid pos-
ition, especially in younger patients. However, with
the advent of percutaneous valve-in-valve implant-
ation, this may be less of a problem in the future.
LATE-ONSET TR
New-onset or worsening TR late after mitral valve
surgery, resulting from an earlier conservative
policy, is an increasingly common phenomenon.w48
Reoperation on the tricuspid valve has a high mor-
tality that some initial reports showed to be up to
50%. For these reasons, many authors recom-
mended medical treatment and postponement of
surgery until right heart failure became refractory
to medication. However, factors for risk at reopera-
tion are high functional class, severe RV failure and
large dimensions of the RV, especially in the
presence of a low EF, and high pulmonary artery
pressure and elevated pulmonary arterial resistance,
all of which are progressive, thus calling for
surgery at an earlier stage. More recently, the
reported mortality of the surgical reintervention has
been much lower, in the order of 10%, and even
lower in others’ and our own experience.w49 w50
Hence, the recent ESC guidelines suggest that
‘surgery should be considered in patients with
severe TR who are asymptomatic or have severe
progressive RV dilatation/dysfunction, in the
absence of left-side valve dysfunction, severe right
or LV dysfunction, and severe pulmonary vascular
disease’ (class IIa).w31 Slightly differently, the ACC/
AHA guidelines classify it as a Class IIb indica-
tion.28 Therefore, there is a need for close
follow-up of patients in this situation and surgery
should be recommended before severe RV dysfunc-
tion occurs (see algorithm in ﬁgure 3). However,
overwhelming comorbidities and limited life
expectancy may be contraindications to perform
surgery.
When surgery is undertaken, there are various
types of access to the tricuspid valve, with the
choice usually residing between repeat sternotomy
and a right thoracotomy. In the former, reopening
of the sternum is sometimes done only after institu-
tion of cardiopulmonary bypass, especially if the
pericardium had not been closed during the previ-
ous operation and the RV is bulging against the
sternum, as seen on the X-ray or CT scan. On the
other hand, the right thoracotomy is becoming
increasingly preferred because it allows a more
direct approach to the valve, after incision of the
fused pericardium and right atrial wall. Minimally
invasive techniques have also been suggested in
these cases.w51 w52
FUTURE, NON-SURGICAL OPTIONS
All percutaneous techniques currently used for
treatment of mitral regurgitation may be adapted to
percutaneous repair or replacement of the TV.w53
These may be based on the tricuspid leaﬂets or
annulus.
Percutaneous edge-to-edge repair, a replication of
the clover technique developed by Alﬁeri et al for
correction of TR in congenitally corrected trans-
position of the great arteries, has been described
and can be used similarly in functional TR, using
the Evalve MitraClip system.w54
The Millipede system, which involves the place-
ment of a ring with an attachment system, via
either minimally invasive surgical or percutaneous
methods, has been tested to restore the native tri-
cuspid annular shape and diameter. The Mitralign
concept of percutaneous mitral repair has been
used for bicuspidisation of the tricuspid valve,
aimed at converting a regurgitating trileaﬂet valve
into a functioning bileaﬂet valve, with some degree
of success.w55
Finally, implantation of a valved stent in the tri-
cuspid position has been described, either as a
primary replacement of the tricuspid valve or to
treat a degenerated bioprosthesis. This can be done
via femoral approach or through direct transatrial
access. Recently, valves in the superior vena cava
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and/or inferior vena cava have been implanted to
prevent damage to the liver and other organs, a
concept previously tested in failing Fontan
circulation.w56
Although the tricuspid valve is more difﬁcult to
access because of its 3D geometry and because of
the large size of the right atrium in these patients,
current 2D and 3D echo imaging technologies
allow easy and accurate placement of all types of
implants in the correct location.
CONCLUSIONS
The most important recent advance in our knowl-
edge in this ﬁeld is that secondary TR is not a truly
functional entity, because it entails intrinsic anatom-
ical abnormalities of the TV apparatus, such as
annular dilatation and deformation.25
Secondary dilatation of the tricuspid annulus is
present in a signiﬁcant number of patients with left
heart valve disease, even in the absence of TR. This
is a progressive disease that does not always resolve
with the correction of the left-side lesion. Tricuspid
intervention at the time of the surgery to the left-
side valve usually helps to improve the functional
capacity without signiﬁcant increase in periopera-
tive mortality and morbidity.
Patients with late appearing severe TR after cor-
rection of left-side lesions need careful follow-up in
order to indicate redo surgery before the develop-
ment of severe RV dysfunction.
Additionally, patients should be maintained on
anticongestive therapy (diuretics and vasodilators),
probably for life, even after successful correction
of TR.
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